Shots:

• The P-III (ADvocate 1 & 2) trial evaluate lebrikizumab as monothx. in adult & adolescent patients aged 12 to ≤18yrs. with mod. to sev. AD
• The results showed that the patients treated with lebrikizumab (q4w & q2w) maintained ≥75% skin improvement (EASI-75) & disease severity @1yr. (79% & 79%) in (ADvocate 1) trial & 85% & 77% in (ADvocate 2) trial, frequency of AEs & overall safety profile were consistent with the induction phase of the trials along with prior studies with no new safety signals
• Additionally, improvements in itch were also observed. The company plans to file a BLA for lebrikizumab in AD to the US FDA in H2’22, followed by submissions to additional regulatory agencies globally while Almirall will submit these results to EMA for authorization in 2022

Ref: Eli Lilly | Image: Eli Lilly